Nxera Pharma Co., Ltd.'s Fiscal Year is From January To December - All Figures are in Days.
The item "Cash-Conversion-Cycle" stands at 398.01 days as of 09/30/2025, the highest value at least since 03/31/2024, the period currently displayed.
As of the end of Nxera Pharma Co., Ltd.'s third quarter, the item "Cash Conversion Cycle" stands at 398.01 Days. This represents an increase of 40.81 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 417.36 compared to the value the year prior.
The Serie's long term average value is 186.22 days. It's latest available value, on 09/30/2025, is 211.79 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 09/30/2024, to it's latest available value, on 09/30/2025, is +417.36 .
The Serie's change from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Cash Conversion Cycle | 905,699,262,464.00 |
![]() | Johnson & Johnson - Cash Conversion Cycle | 486,508,953,600.00 |
![]() | AbbVie Inc - Cash Conversion Cycle | 399,570,305,024.00 |
![]() | Roche Holding AG - Cash Conversion Cycle | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Cash Conversion Cycle | 280,205,508,085.11 |